Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) gains 30% after the company said it will present initial clinical data for ARO-HBV, the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Arrowhead Pharmaceuticals Corp (ARWR) Adds to Gains; Up 57%September 6, 2018 10:44 AM Arrowhead Presents New ARO-HBV Clinical Data Demonstrating HBsAg Reductions at World Gastroenterologists SummitSeptember 6, 2018 7:30 AM